The enzymes in the Invitrogen deal will be used for PCR.

FORBES: Invitrogen Deal Proves Diversa's Worth

The first chemical alone could bring in millions of dollars, making it one of Invitrogen's top sellers, according to Lewis Shuster , Invitrogen's chief operating officer.

FORBES: Invitrogen Deal Proves Diversa's Worth

Before Invitrogen announced it had licensed these chemicals, Diversa had only one product on the market, an enzyme that cleans the hot depths of oil wells.

FORBES: Invitrogen Deal Proves Diversa's Worth

This week it struck a deal to license three chemicals to Invitrogen ivgn (nasdaq: ivgn - news - people), which makes products that accelerate the work of scientists doing genetic research.

FORBES: Invitrogen Deal Proves Diversa's Worth

Life Technologies, formed by the merger last year of life science tools companies Applied Biosystems and Invitrogen, has an estimated 65% of the market for PCR machines used for research and has licensed its technology to 12 other companies making the machines.

FORBES: Technology